Divamics Secures Tens of Millions in Series A Funding to Accelerate AI-Driven Drug Discovery with 'Molecular Movie' Breakthrough

VCBeat learned exclusively that Divamics, an innovator in drug development based on molecular dynamics.Divamics Inc. (hereinafter referred to as "Divamics")Completed tens of millions of yuan in Series A financing, this round of financing was led byYuanBio Venture CapitalLead investment. The funds raised will be used to accelerate the iteration and upgrading of the technology platform and expand the global drug cooperation pipeline.

Divamics, established in 2021, is committed to building an "innovation crucible" for new drug research and development. Through its proprietary "Molecular Movie" algorithm and early drug discovery decision-making platform, it efficiently drives new drug innovation and accelerates the discovery of preclinical compounds. Its core technology and platform significantly reduce the preclinical trial-and-error costs of new drug R&D while increasing speed and success rates.

As a "technical dark horse" in the AIDD (AI Drug Discovery and Design) field, Divamics relies on"Multi-scale Molecular Dynamics + AI Algorithm"The deep integration has already taken place inProtein Degraders, GPCR Targets, Nucleic Acid DrugsBuild differentiated competitiveness in cutting-edge fields. Its core technology system overcomes the limitations of traditional static structure prediction by simulating the dynamic conformational changes of biomolecules (such as protein flexibility, induced fit upon ligand binding), providing atomic-level mechanistic insights for drug design.

Divamics accelerates new drug R&D with lower costs and higher success rates. (Image source: company's official website)

Notably, the company has recently achieved multiple breakthroughs in technology research and development, commercial cooperation, and other aspects——

Technically,Divamics' self-developed first-generation AI drug design algorithm officially receives U.S. patent authorization.The algorithm uses deep learning to model the fingerprint spectrum of each atom type in drugs and target molecules. It is highly interpretable, excels at revealing unknown mechanisms at the molecular level, easily discovers new conformations and binding pockets of allosteric drugs, and can rationally design based on macromolecular flexibility. It is suitable for drug development across different modalities.

Building on this breakthrough,Divamics further completes the framework construction of the world's first kinetic trajectory database.Integrate big data related to drug development, reveal the potential molecular mechanisms behind the pharmacodynamics and pharmacology of different pipelines, efficiently analyze clinical and patent information, and make precise decisions in the logical chain of new drug development. It reshapes the innovation chain from molecular discovery to clinical validation, ensuring that drug molecules have inherent clinical efficacy potential.

In February this year,Divamics Collaborates with Top Research Teams from Peking University School of Pharmaceutical Sciences and Wuhan University of Technology: Research Achievement "Systematic Evolution of Functional Oligonucleotides for Targeted Protein Degradation" Published Online in Chem Journal (a Cell Press journal), providing strong support for the development of novel protein degraders.

In terms of commercialization, Divamics' dual-driven strategy of "deep cultivation in the local market + global expansion" has shown significant results. In the Chinese market,Two drug pipelines合作的两条药物管线, which the company合作with苏州博瑞医药 (Suzhou BrightGene Bio-Medical Technology) and北京鞍石生物 (Beijing Anshi Biotechnology), will分别enter临床Ⅲ期研究 (Phase III clinical trials) in the second half of 2024.

In the international market, since the launch of the overseas strategy in the second half of 2024,Divamics Rapidly Expands Overseas Market, with Overseas Revenue Now Exceeding 60% of the Company's Total Income. Particularly, Since Last Year, a Strategic Cooperation Was Established with a Leading Pharma Enterprise in North America. According to the Contract, the Two Parties Have Initiated Collaboration on 16 Drug Pipelines and Have Successfully Delivered 2 Projects.

With the deepening of international cooperation, the company further breaks through business boundaries,Signed the first "full-package dry and wet lab" order with overseas clients by the end of 2024.By integrating the full-chain capabilities of AI design, dynamic simulation, and experimental validation, it has officially entered a new phase as an integrated solutions provider.

To date, Divamics has established extensive collaborations with over 50 global clients and has participated in more than 80 drug discovery pipelines and projects.

For the acquisition of this round of financing,Founder of Divamics, Zheng ZhenDivamics Expresses: Divamics is extremely honored to partner with YuanBio Venture Capital. This round of investment and financing cooperation is based on the high degree of industrial alignment and synergy between both parties. Divamics is committed to improving the R&D efficiency of innovative drugs. Our unique technical approach deeply integrates AI with physical simulations, aiming for a more precise understanding of the dynamic interactions and mechanisms between drug molecules and targets, enabling rational drug design, predicting efficacy and drug-likeness, and overcoming traditional bottlenecks in drug discovery. Over the past three years, we have continuously iterated and upgraded our core platform, achieving positive results through collaborations with dozens of global enterprises, validating the technical feasibility and potential, and demonstrating a clear value proposition and growth prospects. This round of financing marks further market recognition of the company's technical strength, business model, and team execution capabilities, signifying that the company has entered a more mature stage of value creation. With this financing, we will further expand the types of targets and drug modalities our platform can handle, as well as establish an operational management system to support global strategic partnerships. All members of Divamics will continue to fully commit themselves, driving profound transformation in the pharmaceutical industry through continuous innovation and open collaboration, ultimately benefiting patients worldwide.

Dr. Cheng Gang, Partner of YuanBio Venture CapitalDivamics: The company, based on molecular dynamics models and combined with the latest machine learning and AI technologies, achieves a reasonable balance between simulation accuracy and speed for drug molecule design and optimization. It is applicable to various molecular types, including small molecules, peptides, antibodies, etc., which is expected to greatly improve the efficiency of early-stage drug molecule development. Against the backdrop of strong national support for AI-related industries in China, Divamics' work aligns well with this direction, effectively empowering pharmaceutical R&D enterprises both domestically and internationally. YuanBio Venture Capital looks forward to supporting Divamics in continuous innovation and rapid development, becoming a leading company in the AI-assisted pharmaceutical field in China and even globally.

YuanBio Venture Capital is an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou bioBAY with a global reach. It has invested in over 200 outstanding enterprises in the life sciences field, covering four major areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as cutting-edge medical technologies, achieving substantial investment returns. Among these, 19 companies have gone public on capital markets such as the Hong Kong Stock Exchange and STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, YuanBio Venture Capital possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging professionalism, dedication, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.